Fresenius stock holds steady as earnings and guidance frame the outlook
Published on 08/09/2026 at 14:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Fresenius stock remains a data story for investors, with the company posting EUR 21.5 billion in revenue for 2025 and adjusted EBITDA of EUR 4.0 billion, while reported net income from continuing operations reached EUR 1.0 billion. The company also guided to 4% to 6% organic sales growth and 8% to 12% adjusted EBIT growth for 2026 in its latest investor context.
EUR 21.5 billion revenue
The 2025 revenue base of EUR 21.5 billion gives Fresenius a larger operating platform than a year earlier, and the EUR 4.0 billion adjusted EBITDA figure shows how margin execution still shapes the equity case. A 2025 net income result of EUR 1.0 billion adds another anchor for the companys earnings recovery profile.
2026 guidance stays central
The companys 2026 outlook points to 4% to 6% organic sales growth and 8% to 12% adjusted EBIT growth, which gives the market a concrete range to test against coming quarters. That guidance matters because it sets a clear comparison base for any later revenue, margin, or cash conversion update.
Fresenius investor materials and filing context
Review the latest company investor materials for the revenue, margin, and guidance details that shape Fresenius stock.
Fresenius Kabi matters
Fresenius Kabi remains one of the companys most relevant business lines because it connects the group to clinical nutrition, intravenous generics, and medical products with recurring demand characteristics. For Fresenius stock, the segment is important because group revenue and EBIT growth depend not just on scale, but on where that scale is created.
Stock context without a fresh quote
Fresenius shares are quoted on Xetra under FRES, and the stock market case still comes back to the same numbers: EUR 21.5 billion revenue in 2025, EUR 4.0 billion adjusted EBITDA, and the 4% to 6% sales growth range set for 2026. In that frame, the balance between growth and margin remains more important than a single quarter.
Fresenius at a glance
- Company: Fresenius SE & Co. KGaA
- ISIN: DE0005785604
- Ticker: XETRA: FME
- Trading venue: Xetra
- Sector / Industry: Health Care / Health Care Providers & Services
- Index membership: MDAX
